Cargando…

Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study

As a result of SARS-CoV-2 infection, the host's immune system is disrupted, and chemokines and cytokines are intensified to eliminate the virus, resulting in cytokine storm syndrome and acute respiratory distress syndrome (ARDS). Patients with COVID-19 have been observed to have elevated levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Niki Ghambari, Namaki, Saeed, Hashemi, Seyed Mahmoud, Salehi, Mohammadreza, Ghaffarpour, Sara, Ghazanfari, Tooba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123354/
https://www.ncbi.nlm.nih.gov/pubmed/37148770
http://dx.doi.org/10.1016/j.intimp.2023.110217
_version_ 1785029651592118272
author Mohammadi, Niki Ghambari
Namaki, Saeed
Hashemi, Seyed Mahmoud
Salehi, Mohammadreza
Ghaffarpour, Sara
Ghazanfari, Tooba
author_facet Mohammadi, Niki Ghambari
Namaki, Saeed
Hashemi, Seyed Mahmoud
Salehi, Mohammadreza
Ghaffarpour, Sara
Ghazanfari, Tooba
author_sort Mohammadi, Niki Ghambari
collection PubMed
description As a result of SARS-CoV-2 infection, the host's immune system is disrupted, and chemokines and cytokines are intensified to eliminate the virus, resulting in cytokine storm syndrome and acute respiratory distress syndrome (ARDS). Patients with COVID-19 have been observed to have elevated levels of MCP-1, a chemokine associated with the severity of the disease. In some diseases, polymorphisms in the regulatory region of the MCP-1 gene correspond to serum levels and disease severity. An attempt was made in this study to assess the relationship between MCP-1 G-2518A and serum MCP-1 levels in Iranian COVID-19 patients and the severity of the disease. In this study, patients were randomly sampled from outpatients on the first day of diagnosis and from inpatients on the first day of their hospitalization. Patients were classified into the outpatient (without symptoms or with mild symptoms) and inpatient (with moderate, severe, and critical symptoms) groups. The serum level of MCP-1 was measured by ELISA and the frequency of MCP-1 G-2518A gene polymorphism genotypes in COVID-19 patients was checked by the RFLP-PCR method. Participants with COVID-19 infection had a higher rate of underlying diseases, such as diabetes, high blood pressure, kidney disease, and cardiovascular disease than the control group (P-value < 0.001). Also, the frequency of these factors in inpatients was significantly higher compared to outpatients (P-value < 0.001). Additionally, the level of MCP-1 in serum was significantly different with an average of 11.90 in comparison to 2.98 in the control group (P-value, 0.05), which is attributed to elevated serum levels among patients in hospitals with an average of 11.72 in comparison to 2.98 in the control group. Compared with outpatients, inpatients had a higher frequency of the G allele of the MCP-1-2518 polymorphism (P-value < 0.05), while a notable difference was observed in the serum level of MCP-1 in COVID-19 patients with the MCP-1-2518 AA genotype in the whole group in comparison to the control group (P-value: 0.024). Totally, the results showed that a high frequency of the G allele is related to hospitalization and poor outcome in COVID-19 cases.
format Online
Article
Text
id pubmed-10123354
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-101233542023-04-24 Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study Mohammadi, Niki Ghambari Namaki, Saeed Hashemi, Seyed Mahmoud Salehi, Mohammadreza Ghaffarpour, Sara Ghazanfari, Tooba Int Immunopharmacol Article As a result of SARS-CoV-2 infection, the host's immune system is disrupted, and chemokines and cytokines are intensified to eliminate the virus, resulting in cytokine storm syndrome and acute respiratory distress syndrome (ARDS). Patients with COVID-19 have been observed to have elevated levels of MCP-1, a chemokine associated with the severity of the disease. In some diseases, polymorphisms in the regulatory region of the MCP-1 gene correspond to serum levels and disease severity. An attempt was made in this study to assess the relationship between MCP-1 G-2518A and serum MCP-1 levels in Iranian COVID-19 patients and the severity of the disease. In this study, patients were randomly sampled from outpatients on the first day of diagnosis and from inpatients on the first day of their hospitalization. Patients were classified into the outpatient (without symptoms or with mild symptoms) and inpatient (with moderate, severe, and critical symptoms) groups. The serum level of MCP-1 was measured by ELISA and the frequency of MCP-1 G-2518A gene polymorphism genotypes in COVID-19 patients was checked by the RFLP-PCR method. Participants with COVID-19 infection had a higher rate of underlying diseases, such as diabetes, high blood pressure, kidney disease, and cardiovascular disease than the control group (P-value < 0.001). Also, the frequency of these factors in inpatients was significantly higher compared to outpatients (P-value < 0.001). Additionally, the level of MCP-1 in serum was significantly different with an average of 11.90 in comparison to 2.98 in the control group (P-value, 0.05), which is attributed to elevated serum levels among patients in hospitals with an average of 11.72 in comparison to 2.98 in the control group. Compared with outpatients, inpatients had a higher frequency of the G allele of the MCP-1-2518 polymorphism (P-value < 0.05), while a notable difference was observed in the serum level of MCP-1 in COVID-19 patients with the MCP-1-2518 AA genotype in the whole group in comparison to the control group (P-value: 0.024). Totally, the results showed that a high frequency of the G allele is related to hospitalization and poor outcome in COVID-19 cases. Published by Elsevier B.V. 2023-06 2023-04-24 /pmc/articles/PMC10123354/ /pubmed/37148770 http://dx.doi.org/10.1016/j.intimp.2023.110217 Text en © 2023 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mohammadi, Niki Ghambari
Namaki, Saeed
Hashemi, Seyed Mahmoud
Salehi, Mohammadreza
Ghaffarpour, Sara
Ghazanfari, Tooba
Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title_full Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title_fullStr Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title_full_unstemmed Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title_short Impact of the MCP-1-2518A>G polymorphism on COVID-19 severity in the Iranian population: A case-control study
title_sort impact of the mcp-1-2518a>g polymorphism on covid-19 severity in the iranian population: a case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123354/
https://www.ncbi.nlm.nih.gov/pubmed/37148770
http://dx.doi.org/10.1016/j.intimp.2023.110217
work_keys_str_mv AT mohammadinikighambari impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy
AT namakisaeed impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy
AT hashemiseyedmahmoud impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy
AT salehimohammadreza impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy
AT ghaffarpoursara impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy
AT ghazanfaritooba impactofthemcp12518agpolymorphismoncovid19severityintheiranianpopulationacasecontrolstudy